文献速递艾滋病与性传播感染

中低收入国家一线抗逆转录病毒治疗启动或重启前的HIV-1耐药性:系统综述与元回归分析

HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
PubMed 文献 · Lancet Infect Dis · 2017-12-05

2016年撒哈拉以南非洲和拉丁美洲的预处理NNRTI耐药率接近WHO 10%的换线阈值,且各区域逐年显著上升。

要点

  • 所有区域预处理NNRTI耐药逐年增加,南部非洲年比值比增加23%。
  • 需加强国家HIV耐药监测并审视一线ART方案组成。

核心结论

  • 中低收入国家预处理耐药正以可观速度增加,尤其在撒哈拉以南非洲。
  • 2016年南部非洲、东部非洲和拉丁美洲的预处理NNRTI耐药率接近WHO 10%的更换一线ART阈值。

主要发现

  • 预处理耐药年比值比增加:南部非洲23%(95%CI 16-29),东部非洲17%(5-30),西部和中部非洲17%(6-29),拉丁美洲和加勒比11%(5-18),亚洲11%(2-20)。

关键数值与推荐

  • WHO关于更换一线ART的预处理NNRTI耐药阈值为10%。

临床怎么用

  • 应开展常规国家HIV耐药监测。
  • 需审视国家一线ART方案组成政策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pretreatment drug resistance in people initiating or re-initiating antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV control in low-income and middle-income countries (LMICs). We aimed to assess the scale of this problem and whether it is associated with the intiation or re-initiation of ART in people who have had previous exposure to antiretroviral drugs. METHODS: This study was a systematic review and meta-regression analysis. We assessed regional prevalence of pretreatment drug resistance and risk of pretreatment drug resistance in people initiating ART who reported previous ART exposure. We systematically screened publications and unpublished datasets for pretreatment drug-resistance data in individuals in LMICs initiating or re-initiating first-line ART from LMICs. We searched for studies in PubMed and Embase and conference abstracts and presentations from the Conference on Retroviruses and Opportunistic Infections, the International AIDS Society Conference, and the International Drug Resistance Workshop for the period Jan 1, 2001, to Dec 31, 2016. To assess the prevalence of drug resistance within a specified region at any specific timepoint, we extracted study level data and pooled prevalence estimates within the region using an empty logistic regression model with a random effect at the study level. We used random effects meta-regression to relate sampling year to prevalence of pretreatment drug resistance within geographical regions. FINDINGS: We identified 358 datasets that contributed data to our analyses, representing 56 044 adults in 63 countries. Prevalence estimates of pretreatment NNRTI resistance in 2016 were 11·0% (7·5-15·9) in southern Africa, 10·1% (5·1-19·4) in eastern Africa, 7·2% (2·9-16·5) in western and central Africa, and 9·4% (6·6-13·2) in Latin America and the Caribbean. There were substantial increases in pretreatment NNRTI resistance per year in all regions. The yearly increases in the odds of pretreatment drug resistance were 23% (95% CI 16-29) in southern Africa, 17% (5-30) in eastern Africa, 17% (6-29) in western and central Africa, 11% (5-18) in Latin America and the Caribbean, and 11% (2-20) in Asia. Estimated increases in the absolute prevalence of pretreatment drug resistance between 2015 and 2016 ranged from 0·3% in Asia to 1·8% in southern Africa. INTERPRETATION: Pretreatment drug resistance is increasing at substantial rate in LMICs, especially in sub-Saharan Africa. In 2016, the prevalence of pretreatment NNRTI resistance was near WHO's 10% threshold for changing first-line ART in southern and eastern Africa and Latin America, underscoring the need for routine national HIV drug-resistance surveillance and review of national policies for first-line ART regimen composition. FUNDING: Bill & Melinda Gates Foundation and World Health Organization.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2017. PMID: 29198909. doi:10.1016/S1473-3099(17)30702-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。